Phaseline

Companies › Orphalan

Orphalan: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TETA 4HCl
Copper chelator
ATP7BPhase 3Wilson's DiseaseFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07465718TETA 4HClPhase 3Wilson's DiseaseMetabolic and endocrineFeb 2028

Targets

ATP7B (1)

Companies with the same targets

Vivet Therapeutics SAS Ultragenyx Pharmaceutical Prime Medicine

Companies built like this

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Lumos Pharma Neuvosyn Laboratories

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.